相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mesenchymal stem cells from different sources and their derived exosomes: A pre-clinical perspective
Maria Alvarez-Viejo
WORLD JOURNAL OF STEM CELLS (2020)
Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
Cosimo Cumbo et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors
Jee Hyun Kong et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Exosomal Transfer of LCP1 Promotes Osteosarcoma Cell Tumorigenesis and Metastasis by Activating the JAK2/STAT3 Signaling Pathway
Xuhui Ge et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2020)
Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options
Daniel Nisakar Meenakshi Sundaram et al.
DRUG DISCOVERY TODAY (2019)
Extracellular Vesicles-Encapsulated MicroRNA-125b Produced in Genetically Modified Mesenchymal Stromal Cells Inhibits Hepatocellular Carcinoma Cell Proliferation
Silvia Baldari et al.
CELLS (2019)
Molecular screening and the clinical impacts of BCR-ABL KD mutations in patients with imatinib-resistant chronic myeloid leukemia
Betul Kockan et al.
ONCOLOGY LETTERS (2018)
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment
Masaya Okada et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Exosomes from mesenchymal stromal cells enhance imatinib-induced apoptosis in human leukemia cells via activation of caspase signaling pathway
Ying Liu et al.
CYTOTHERAPY (2018)
Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
Oliver Ottmann et al.
BLOOD CANCER JOURNAL (2018)
Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors
Koji Sasaki et al.
CANCER (2016)
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A. Hochhaus et al.
LEUKEMIA (2016)
MiR-15a/16 regulates the growth of myeloma cells, angiogenesis and antitumor immunity by inhibiting Bcl-2, VEGF-A and IL-17 expression in multiple myeloma
Yanjie Li et al.
LEUKEMIA RESEARCH (2016)
Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation
Jean Claude Chomel et al.
ONCOTARGET (2016)
Mesenchymal Stem Cell-Derived Extracellular Vesicles Promote Angiogenesis: Potencial Clinical Application
Consuelo Merino-Gonzalez et al.
FRONTIERS IN PHYSIOLOGY (2016)
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
T. P. Hughes et al.
LEUKEMIA (2015)
Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway
X. Li et al.
ARCHIVES OF TOXICOLOGY (2015)
Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells
Jinheng Wang et al.
BLOOD (2014)
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia
Concetta Quintarelli et al.
LEUKEMIA RESEARCH (2014)
Bone Marrow Mesenchymal Stem Cell-Derived Microvesicles Protect Rat Pheochromocytoma PC12 Cells from Glutamate-Induced Injury via a PI3K/Akt Dependent Pathway
Shan-Shan Lin et al.
NEUROCHEMICAL RESEARCH (2014)
Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells
Makiko Ono et al.
SCIENCE SIGNALING (2014)
New insights in cellular and molecular aspects of BM niche in chronic myelogenous leukemia
Saeid Shahrabi et al.
TUMOR BIOLOGY (2014)
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling
Bin Zhang et al.
BLOOD (2013)
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression
Aldo M. Roccaro et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Microvesicles Derived from Human Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Attenuate Bladder Tumor Cell Growth In Vitro and In Vivo
Shuai Wu et al.
PLOS ONE (2013)
Microvesicles Derived from Human Bone Marrow Mesenchymal Stem Cells Inhibit Tumor Growth
Stefania Bruno et al.
STEM CELLS AND DEVELOPMENT (2013)
Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia
Bin Zhang et al.
CANCER CELL (2012)
Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo
Wei Zhu et al.
CANCER LETTERS (2012)
Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts
Y. Tabe et al.
LEUKEMIA (2012)
MYC in Chronic Myeloid Leukemia: Induction of Aberrant DNA Synthesis and Association with Poor Response to Imatinib
Marta Albajar et al.
MOLECULAR CANCER RESEARCH (2011)
p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells
L. F. Peterson et al.
LEUKEMIA (2011)
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML
Rajesh R. Nair et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis
Fabrizio Vianello et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
NJ Donato et al.
BLOOD (2003)
分享论文
